PMV Pharmaceuticals, Inc today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences in June.
PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharma, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences in June. Management will also participate in one-on-one investor meetings.
Jefferies Global Healthcare Conference (June 5 – 6, 2024)
Format: Fireside Chat
Date: Thursday, June 6, 2024
Time: 2:00 – 2:25 PM ET
Goldman Sachs 45th Annual Global Healthcare Conference (June 10 – 13, 2024)
Format: Fireside Chat
Date: Wednesday, June 12, 2024
Time: 9:20 – 9:55 AM ET
A live audio webcast of the event will be available online at Events & Presentations. An archived replay of the event will be available for 90 days following the webcast at Events & Presentations.
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.
Investors Contact:
Tim Smith
Senior Vice President, Head of Corporate Development and Investor Relations
investors@pmvpharma.com
Media Contact:
Kathy Vincent
Greig Communications
kathy@greigcommunications.com
